|
1
|
Strioga M, Pasukoniene V and Characiejus
D: CD8+ CD28- and CD8+ CD57+ T cells and their role in health and
disease. Immunology. 134:17–32. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wu RC, Hwu P and Radvanyi LG: New insights
on the role of CD8(+)CD57(+) T-cells in cancer. Oncoimmunology.
1:954–956. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Brenchley JM, Karandikar NJ, Betts MR,
Ambrozak DR, Hill BJ, Crotty LE, Casazza JP, Kuruppu J, Migueles
SA, Connors M, et al: Expression of CD57 defines replicative
senescence and antigen-induced apoptotic death of CD8+ T cells.
Blood. 101:2711–2720. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Papagno L, Spina CA, Marchant A, Salio M,
Rufer N, Little S, Dong T, Chesney G, Waters A, Easterbrook P, et
al: Immune activation and CD8+ T-cell differentiation towards
senescence in HIV-1 infection. PLoS Biol. 2:E202004. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Akagi J and Baba H: Prognostic value of
CD57(+) T lymphocytes in the peripheral blood of patients with
advanced gastric cancer. Int J Clin Oncol. 13:528–535. 2008.
View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Characiejus D, Pasukoniene V,
Jonusauskaite R, Azlauskaite N, Aleknavicius E, Mauricas M and
Otter WD: Peripheral blood CD8highCD57+ lymphocyte levels may
predict outcome in melanoma patients treated with adjuvant
interferon-alpha. Anticancer Res. 28:1139–1142. 2008.PubMed/NCBI
|
|
7
|
Characiejus D, Pasukoniene V, Kazlauskaite
N, Valuckas KP, Petraitis T, Mauricas M and Den Otter W: Predictive
value of CD8highCD57+ lymphocyte subset in interferon therapy of
patients with renal cell carcinoma. Anticancer Res. 22:3679–3683.
2002.PubMed/NCBI
|
|
8
|
Dondi E, Roué G, Yuste VJ, Susin SA and
Pellegrini S: A dual role of IFN-alpha in the balance between
proliferation and death of human CD4+ T lymphocytes during primary
response. J Immunol. 173:3740–3747. 2004. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Cosmi L, Liotta F, Lazzeri E, Francalanci
M, Angeli R, Mazzinghi B, Santarlasci V, Manetti R, Vanini V and
Romagnani P: Human CD8+CD25+ thymocytes share phenotypic and
functional features with CD4+CD25+ regulatory thymocytes. Blood.
102:4107–4114. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Chaput N, Louafi S, Bardier A, Charlotte
F, Vaillant JC, Ménégaux F, Rosenzwajg M, Lemoine F, Klatzmann D
and Taieb J: Identification of CD8+CD25+Foxp3+ suppressive T cells
in colorectal cancer tissue. Gut. 58:520–529. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Billerbeck E, Blum HE and Thimme R:
Parallel expansion of human virus-specific FoxP3-effector memory
and de novo-generated FoxP3+ regulatory CD8+ T cells upon antigen
recognition in vitro. J Immunol. 179:1039–1048. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Simone R, Zicca A and Saverino D: The
frequency of regulatory CD3+CD8+CD28-CD25+ T lymphocytes in human
peripheral blood increases with age. J Leukoc Biol. 84:1454–1461.
2008. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Gavin MA, Torgerson TR, Houston E, DeRoos
P, Ho WY, Stray-Pedersen A, Ocheltree EL, Greenberg PD, Ochs HD and
Rudensky AY: Single-cell analysis of normal and FOXP3-mutant human
T cells: FOXP3 expression without regulatory T cell development.
Proc Natl Acad Sci USA. 103:6659–6664. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
14
|
Allan SE, Song-Zhao GX, Abraham T,
McMurchy AN and Levings MK: Inducible reprogramming of human T
cells into Treg cells by a conditionally active form of FOXP3. Eur
J Immunol. 38:3282–3289. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Pillai V and Karandikar NJ: Human
regulatory T cells: A unique, stable thymic subset or a reversible
peripheral state of differentiation? Immunol Lett. 114:9–15. 2007.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Guo L, Tian J, Marinova E, Zheng B and Han
S: Inhibition of clonal expansion by Foxp3 expression as a
mechanism of controlled T-cell responses and autoimmune disease.
Eur J Immunol. 40:71–80. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Sobin LH and Wittekind CH: TNM
classification of malignant tumours. John Wiley and Sons; New York:
1997
|
|
18
|
Takayama T, Sekine T, Makuuchi M, Yamasaki
S, Kosuge T, Yamamoto J, Shimada K, Sakamoto M, Hirohashi S, Ohashi
Y and Kakizoe T: Adoptive immunotherapy to lower postsurgical
recurrence rates of hepatocellular carcinoma: A randomised trial.
Lancet. 356:802–807. 2000. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
Trotti A, Colevas AD, Setser A, Rusch V,
Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN and
Rubin P: CTCAE v3.0: Development of a comprehensive grading system
for the adverse effects of cancer treatment. Semin Radiat Oncol.
13:176–181. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Wischhusen J, Jung G, Radovanovic I, Beier
C, Steinbach JP, Rimner A, Huang H, Schulz JB, Ohgaki H and Aguzzi
A: Identification of CD70-mediated apoptosis of immune effector
cells as a novel immune escape pathway of human glioblastoma.
Cancer Res. 62:2592–2599. 2002.PubMed/NCBI
|
|
21
|
Nolte MA, van Olffen RW, van Gisbergen KP
and van Lier RA: Timing and tuning of CD27-CD70 interactions: The
impact of signal strength in setting the balance between adaptive
responses and immunopathology. Immunol Rev. 229:216–231. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Claus C, Riether C, Schürch C, Matter MS,
Hilmenyuk T and Ochsenbein AF: CD27 signaling increases the
frequency of regulatory T cells and promotes tumor growth. Cancer
Res. 72:3664–3676. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Anichini A, Molla A, Vegetti C, Bersani I,
Zappasodi R, Arienti F, Ravagnani F, Maurichi A, Patuzzo R and
Santinami M: Tumor-reactive CD8+ early effector T cells identified
at tumor site in primary and metastatic melanoma. Cancer Res.
70:8378–8387. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Campbell DJ and Ziegler SF: FOXP3 modifies
the phenotypic and functional properties of regulatory T cells. Nat
Rev Immunol. 7:305–310. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Billerbeck E, Nakamoto N, Seigel B, Blum
HE, Chang KM and Thimme R: Determinants of in vitro expansion of
different human virus-specific FoxP3+ regulatory CD8+ T cells in
chronic hepatitis C virus infection. J Gen Virol. 90:1692–1701.
2009. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Duggleby RC, Shaw TN, Jarvis LB, Kaur G
and Gaston JS: CD27 expression discriminates between regulatory and
non-regulatory cells after expansion of human peripheral blood CD4+
CD25+ cells. Immunology. 121:129–139. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Vlad G, King J, Chang CC, Liu Z, Friedman
RA, Torkamani AA and Suciu-Foca N: Gene profile analysis of CD8
(+) ILT3-Fc induced T suppressor cells. Hum Immunol.
72:107–114. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Matter M, Odermatt B, Yagita H, Nuoffer JM
and Ochsenbein AF: Elimination of chronic viral infection by
blocking CD27 signaling. J Exp Med. 203:2145–2155. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Penaloza-MacMaster P, Rasheed Ur A, Iyer
SS, Yagita H, Blazar BR and Ahmed R: Opposing effects of CD70
costimulation during acute and chronic lymphocytic choriomeningitis
virus infection of mice. J Virol. 85:6168–6174. 2011. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Borst J, Hendriks J and Xiao Y: CD27 and
CD70 in T cell and B cell activation. Curr Opin Immunol.
17:275–281. 2005. View Article : Google Scholar : PubMed/NCBI
|
|
31
|
Yang ZZ, Novak AJ, Ziesmer SC, Witzig TE
and Ansell SM: CD70+ non-Hodgkin lymphoma B cells induce Foxp3
expression and regulatory function in intratumoral CD4+CD25 T
cells. Blood. 110:2537–2544. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Jak M, Mous R, Remmerswaal EB, Spijker R,
Jaspers A, Yagüe A, Eldering E, Van Lier RA and Van Oers MH:
Enhanced formation and survival of CD4+ CD25hi Foxp3+ T-cells in
chronic lymphocytic leukemia. Leuk Lymphoma. 50:788–801. 2009.
View Article : Google Scholar : PubMed/NCBI
|
|
33
|
He LZ, Prostak N, Thomas LJ, Vitale L,
Weidlick J, Crocker A, Pilsmaker CD, Round SM, Tutt A and Glennie
MJ: Agonist anti-human CD27 monoclonal antibody induces T cell
activation and tumor immunity in human CD27-transgenic mice. J
Immunol. 191:4174–4183. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
He LZ, Wasiuk A, Testa J, Weidlick J,
Sisson C, Crocker A, Widger J, Forsberg E, Gergel L, Thomas L, et
al: The mechanism of anti-tumor immunity induced by varlilumab, a
CD27 agonist mAb, is model dependent. J Immunother Cancer. 3 Suppl
2:P1882015. View Article : Google Scholar
|
